Up 18% In A Month, Will Allogene Therapeutics Stock See Higher Levels?
- Tuesday, April 5, 2022, 7:24
- Market
- Add a comment
The stock price of Allogene Therapeutics, a biotechnology company focused on T-cell therapies for solid tumors, has seen an 18% rise over the last month, white it’s down 38% YTD. The stock price over the recent weeks has been buoyed by the U.S. FDA assigning fast track designation to its ALLO-316…
About the Author
admin123 has written 23519 stories on this site.
